Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 1
2013 1
2015 3
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Cutaneous tuberculosis in patients with AIDS.
Oliva SM, Redini L, Bases OM, Ortega G, Messina OG, Maranzana A, Carlevaro RO, Benetucci JA. Oliva SM, et al. Among authors: messina og. AIDS Patient Care STDS. 1997 Dec;11(6):443-9. doi: 10.1089/apc.1997.11.443. AIDS Patient Care STDS. 1997. PMID: 11361866 Review. No abstract available.
Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.
Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, Furrer H, Miller RF, Losso MH, Toibaro J, Miro JM, Vassilenko A, Girardi E, Bruyand M, Obel N, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group in EuroCoord. Podlekareva DN, et al. Lancet HIV. 2016 Mar;3(3):e120-31. doi: 10.1016/S2352-3018(15)00252-0. Epub 2016 Feb 2. Lancet HIV. 2016. PMID: 26939735 Free article.
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 Study Group. Dickinson L, et al. Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156. Epub 2015 Jul 14. Clin Pharmacol Ther. 2015. PMID: 26044067 Free PMC article. Clinical Trial.
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.
SECOND-LINE Study Group; Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA. SECOND-LINE Study Group, et al. Lancet. 2013 Jun 15;381(9883):2091-9. doi: 10.1016/S0140-6736(13)61164-2. Lancet. 2013. PMID: 23769235 Clinical Trial.
Lethal leptospiral pulmonary hemorrhage: an emerging disease in Buenos Aires, Argentina.
Seijo A, Coto H, San Juan J, Videla J, Deodato B, Cernigoi B, Messina OG, Collia O, de Bassadoni D, Schtirbu R, Olenchuk A, de Mazzonelli GD, Parma A. Seijo A, et al. Among authors: messina og. Emerg Infect Dis. 2002 Sep;8(9):1004-5. doi: 10.3201/eid0809.010499. Emerg Infect Dis. 2002. PMID: 12194784 Free PMC article. No abstract available.
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
ENCORE1 Study Group; Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S. ENCORE1 Study Group, et al. Lancet Infect Dis. 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5. Epub 2015 Apr 12. Lancet Infect Dis. 2015. PMID: 25877963 Clinical Trial.